$6.69 Million in Sales Expected for Seres Therapeutics Inc (NASDAQ:MCRB) This Quarter

Equities analysts predict that Seres Therapeutics Inc (NASDAQ:MCRB) will announce sales of $6.69 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Seres Therapeutics’ earnings. The lowest sales estimate is $3.00 million and the highest is $9.26 million. Seres Therapeutics posted sales of $9.06 million during the same quarter last year, which would indicate a negative year over year growth rate of 26.2%. The business is scheduled to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that Seres Therapeutics will report full-year sales of $31.96 million for the current year, with estimates ranging from $22.32 million to $38.37 million. For the next year, analysts forecast that the company will post sales of $39.68 million, with estimates ranging from $18.70 million to $56.50 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.17. The business had revenue of $12.53 million during the quarter, compared to the consensus estimate of $10.29 million.

A number of equities research analysts have recently issued reports on MCRB shares. Cantor Fitzgerald reissued a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, May 7th. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Seres Therapeutics in a research report on Friday, May 3rd. BidaskClub cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd. Finally, Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.25.

In other news, Director Noubar Afeyan acquired 8,888,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was acquired at an average price of $2.25 per share, with a total value of $19,999,998.00. Following the completion of the transaction, the director now directly owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 37.00% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of MCRB. Tower Research Capital LLC TRC lifted its position in Seres Therapeutics by 3,656.7% during the second quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 8,447 shares during the period. BNP Paribas Arbitrage SA lifted its position in Seres Therapeutics by 945.5% during the first quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,924 shares during the period. SG Americas Securities LLC bought a new stake in Seres Therapeutics during the second quarter worth about $34,000. Parametric Portfolio Associates LLC bought a new stake in Seres Therapeutics during the second quarter worth about $42,000. Finally, A.R.T. Advisors LLC bought a new stake in Seres Therapeutics during the second quarter worth about $64,000.

Shares of Seres Therapeutics stock traded up $0.34 during trading on Wednesday, reaching $3.31. The company’s stock had a trading volume of 277,229 shares, compared to its average volume of 414,186. The business’s 50-day moving average price is $2.85 and its 200-day moving average price is $4.70. The firm has a market cap of $199.25 million, a PE ratio of -1.36 and a beta of 2.03. Seres Therapeutics has a 52 week low of $2.02 and a 52 week high of $9.26.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: Ex-Dividend

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.